Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection and hospitalization in infants worldwide, with a substantial clinical and socioeconomic burden. For decades, preventive strategies were limited to high-risk populations, with minimal impact at the population level. Recent advances in RSV virology and immunology have transformed prevention. This review summarizes RSV epidemiology, key pathogenetic mechanisms, and current preventive strategies, with a focus on long-acting monoclonal antibodies and maternal vaccination. Evidence from randomized clinical trials, real-world studies, and international recommendations is critically appraised, with emphasis on implementation strategies and emerging preventive tools. These developments mark a shift from risk-based prophylaxis to broader, population-level prevention, with the potential to substantially reduce RSV-related morbidity and healthcare burden in early childhood.

RSV in children: an evolving story from high burden to universal prevention / Spatuzzo, M., Manzoni, P., Nenna, R., Petrarca, L., Frassanito, A., Conti, M.G., Mancino, E., La Regina, D.P., Matera, L., Bonci, E., Midulla, F.. - In: PAEDIATRIC RESPIRATORY REVIEWS. - ISSN 1526-0542. - (2026). [10.1016/j.prrv.2026.09.005]

RSV in children: an evolving story from high burden to universal prevention

Spatuzzo M.
Primo
;
Nenna R.;Petrarca L.;Frassanito A.;Conti M. G.;Mancino E.;Matera L.;Bonci E.;Midulla F.
2026

Abstract

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection and hospitalization in infants worldwide, with a substantial clinical and socioeconomic burden. For decades, preventive strategies were limited to high-risk populations, with minimal impact at the population level. Recent advances in RSV virology and immunology have transformed prevention. This review summarizes RSV epidemiology, key pathogenetic mechanisms, and current preventive strategies, with a focus on long-acting monoclonal antibodies and maternal vaccination. Evidence from randomized clinical trials, real-world studies, and international recommendations is critically appraised, with emphasis on implementation strategies and emerging preventive tools. These developments mark a shift from risk-based prophylaxis to broader, population-level prevention, with the potential to substantially reduce RSV-related morbidity and healthcare burden in early childhood.
2026
Maternal vaccination; Monoclonal antibodies; RSV prevention; Respiratory Syncytial Virus
01 Pubblicazione su rivista::01a Articolo in rivista
RSV in children: an evolving story from high burden to universal prevention / Spatuzzo, M., Manzoni, P., Nenna, R., Petrarca, L., Frassanito, A., Conti, M.G., Mancino, E., La Regina, D.P., Matera, L., Bonci, E., Midulla, F.. - In: PAEDIATRIC RESPIRATORY REVIEWS. - ISSN 1526-0542. - (2026). [10.1016/j.prrv.2026.09.005]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1781643
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact